...
首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >Intermittent subcutaneous methadone administration in the management of cancer pain.
【24h】

Intermittent subcutaneous methadone administration in the management of cancer pain.

机译:间歇性皮下美沙酮管理在癌症疼痛的管理中。

获取原文
获取原文并翻译 | 示例
           

摘要

Methadone is a strong opioid analgesic that has been used successfully in cancer pain management. The oral route of administration is generally preferred for opioid analgesics. However that route sometimes cannot be used. Experience with continuous subcutaneous methadone infusions has produced local intolerance. The aim of this study was to analyze the use of intermittent subcutaneous methadone injections. Ten patients whose pain was well-controlled with oral methadone (average dose 30 mg, range 10 to 120 mg) participated in the study. A subcutaneous small vein needle (butterfly) was used exclusively for administration of methadone. Over a period of seven days the local discomfort of each injection was evaluated by means of a Verbal Numerical Rating Scale (NRS) and the site of infusion was observed. When any degree of erythema or inflammation was seen, the infusion site was changed. The initial subcutaneous dose was the same as the previously administered oral dose. A daily record was kept of the dose used, level of pain, and toxicity symptoms. This close vigilance was aimed at avoiding dosage errors due to variations among individuals in acceptance to previous oral medication. Changes in dosage were allowed according to standard medical criteria. Two patients were withdrawn from the study due to non-painful irritation at the infusion point. Another eight patients tolerated repeated administration of subcutaneous methadone over seven days. Any local irritation from subcutaneous methadone that occurred was managed satisfactorily by changing the infusion site and limiting doses to 30 mg. In seven of 182 repeat administration, injection site changes were necessitated by local irritation. The NRS for local discomfort was 2/10. The two patients who were intolerant of the subcutaneous injections were receiving injected doses which were significantly higher than the others (42 mg as compared to 25 mg). Dose adjustments needed when changing from the oral to the subcutaneous methadone route were minimal. Subcutaneous intermittent administration of methadone appears to be a useful alternative to oral administration in selected clinical situations when oral administration is not feasible.
机译:美沙酮是一种强大的阿片类镇痛药,已在癌症疼痛管理中成功使用。对于阿片类药物镇痛药,通常优选施用口腔途径。但是,途径有时不能使用。连续皮下甲醚输注的经验产生了局部不耐受。本研究的目的是分析间歇皮下甲酮注射的使用。 10名患者与口服美沙酮疼痛的疼痛(平均剂量为30mg,10至120mg)参与了该研究。皮下小静脉针(蝴蝶)专门用于给予美沙酮。在七天内,通过口头数值评定量表(NRS)评估每个注射的局部不适,并且观察输注部位。当看到任何程度的红斑或炎症时,输液部位发生了变化。初始皮下剂量与先前给药的口服剂量相同。每日记录被用过的剂量,疼痛水平和毒性症状。这种紧张的警惕旨在避免由于个体的变异因子接受前以前口腔用药而导致的剂量误差。根据标准医学标准允许剂量的变化。由于输注点的非疼痛刺激,从研究中取出了两名患者。另外8名患者耐受重复施用皮下美沙酮7天。通过改变输注部位和限制剂量至30毫克,将发生皮下美沙酮的局部刺激令人满意地管理。在182人重复的7个中,局部刺激需要注射部位变化。本地不适的NRS是2/10。两种患者的皮下注射的患者接受注射剂量,其显着高于其他剂量(42毫克,与25mg相比)。当从口腔切换到皮下美沙酮途径时需要调节剂量最小。当口服给药不可行时,皮下间歇施用美沙酮似乎是在选定的临床局势中口服给药的有用替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号